• March 12, 2014 - N30 Announces Start of Oral Dosing of N91115 in a Phase 1 Clinical Trial
  • October 15, 2013 - N30 Announces Presentations at the 2013 North American Cystic Fibrosis Conference
  • April 2, 2013 - N30 Announces Presentation of Preclinical Data at the Basic Science Meeting of the European Cystic Fibrosis Society
  • March 13, 2013 - N30 Announces First Patient Treated in Clinical Trial of N6022 in Cystic Fibrosis
  • October 8, 2012 - N30 Names Sherif Gabriel, Ph.D. as VP Research
  • October 9, 2014 - Safety, Tolerability, and Pharmacokinetics of the Oral S-Nitrosoglutathione Reductase Inhibitor N91115: A Multiple Ascending-Dose Study In Healthy Subjects
  • October 9, 2014 - Safety, Tolerability, and Pharmacokinetics of the Intravenous S-NitrosoglutathioneReductaseInhibitor N6022: An Ascending-Dose Study in Subjects Homozygous for the F508del-CFTRMutation
  • October 4, 2014 - Pharmacological Correction and Acute Inhibition of GSNOR Results in Improved In Vitro CFTR Function
  • October 4, 2014 - Neutrophil Elastase-Mediated CFTR Damage is Rescued by Intracellular Bioavailable GSNO
  • March 21, 2014 - Primary airway epithelial cells expanded with feeder cells and ROCK inhibitor for screening novel GSNOR inhibitors and CFTR correctors
More posters

Home

N30 Pharmaceuticals

N30 Pharmaceuticals Boulder Colorado headquarters

N30 Pharmaceuticals

Founded in 2007 with headquarters in Boulder, Colorado.

N30 Pharma is developing a novel class of disease modifying therapies with a focus on cystic fibrosis.  The new therapies preserve intracellular GSNO (S-nitrosoglutathione), a key regulator of CFTR (cystic fibrosis transmembrane conductance regulator) trafficking and stability.

Decreased GSNO levels are associated with cystic fibrosis, and with increased activity of GSNOR (GSNO reductase), the primary catabolizing enzyme of GSNO.

N30 Pharma has developed a broad portfolio of proprietary, potent, small molecule inhibitors of GSNOR that modulate F508del-CFTR activity.

Cystic Fibrosis

  • GSNO levels affect trafficking and stability of CFTR, the transmembrane regulator protein that is defective in cystic fibrosis
  • GSNO inhibitors have been shown to increase CFTR function using in vitro and in vivo experimental models of cystic fibrosis, and have additive effects when combined with several different CFTR correctors and potentiators
  • Anti-inflammatory effects of GSNOR inhibitors relevant to cystic fibrosis include decreased NFκB activation, neutrophilic infiltration, and elastase-mediated lung injuryLead compound, oral N91115, is progressing though Phase 1 testing in healthy subjects with studies in cystic fibrosis patients targeted for the second half of 2014
  • Lead compound, oral N91115, is progressing though Phase 1 testing in healthy subjects with studies in cystic fibrosis patients targeted for the second half of 2014